Author Interviews, Cannabis, JAMA, Opiods / 13.11.2025
Cancer Patients May Be able to Manage Pain with Cannabis Instead of Opioids
[caption id="attachment_71419" align="alignleft" width="150"]
Victoria Bethel[/caption]
MedicalResearch.com Interview with:
Victoria Bethel, MSN
Department of Public Administration and Policy
University of Georgia, Athens
MedicalResearch.com: What is the background for this study?
Response: From the same pool of commercially insured patients, we found that cannabis dispensary openings were associated with reduced opioid prescribing among patients with non-cancer pain.
For this study, we examined whether cannabis dispensary openings were also associated with reduced opioid prescribing among commercially insured patients who do have a cancer diagnosis.
Similar to patients without cancer, we estimated reductions in opioid prescribing after medical and recreational cannabis dispensaries open. These findings may suggest that patients who experience cancer pain are able to manage their pain with cannabis instead of requiring opioids, although we cannot directly observe substitution.
Victoria Bethel[/caption]
MedicalResearch.com Interview with:
Victoria Bethel, MSN
Department of Public Administration and Policy
University of Georgia, Athens
MedicalResearch.com: What is the background for this study?
Response: From the same pool of commercially insured patients, we found that cannabis dispensary openings were associated with reduced opioid prescribing among patients with non-cancer pain.
For this study, we examined whether cannabis dispensary openings were also associated with reduced opioid prescribing among commercially insured patients who do have a cancer diagnosis.
Similar to patients without cancer, we estimated reductions in opioid prescribing after medical and recreational cannabis dispensaries open. These findings may suggest that patients who experience cancer pain are able to manage their pain with cannabis instead of requiring opioids, although we cannot directly observe substitution.
Scott Kaplan PhD
Assistant Professor of Economics
United States Naval Academy
Annapolis, MD 21402
MedicalResearch.com: What is the background for this study?
Response: Sugar-sweetened beverages (colloquially known as SSBs), which include sodas, fruit drinks, sports drinks, energy drinks, and sweetened coffee drinks, are the leading source of added sugars in the American diet, according to the CDC. They are associated with serious negative health outcomes, including type 2 diabetes, obesity, heart disease, kidney disease,
Joanna Jiang, PhD
Agency for Healthcare Research and Quality
Rockville, Maryland
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Over the last decade we have seen two trends occurring to rural hospitals – closures and mergers. A hospital in financial distress could likely face closure. But if the hospital affiliates with a multihospital system, it may have access to resources from the system that help shelter the hospital from closure.
That is exactly what we found in this study. System affiliation was associated with a lower risk of closure for financially distressed hospitals. However, among hospitals that were financially stable, system affiliation was associated with a higher risk of closure. This is somewhat puzzling and needs further study to better understand the reason for closure.
Dr. Eberly[/caption]
Lauren A. Eberly, MD, MPH
Clinical Fellow, Cardiovascular Medicine
Perelman School of Medicine
Cardiovascular Division, Perelman School of Medicine
Center for Cardiovascular Outcomes, Quality, and Evaluative Research,
Cardiovascular Center for Health Equity and Social Justice,
Leonard Davis Institute of Health Economics
University of Pennsylvania, Philadelphia
MedicalResearch.com: What is the background for this study?
Response: Racial inequities are pervasive in our country, and cardiovascular therapeutics with proven benefit have been shown to be underutilized among Black and Latinx patients.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recommended treatment option for glycemic control in patients with diabetes, have recently emerged as a cardioprotective therapy as multiple large randomized clinical trials have shown they prevent cardiovascular events among patients with Type 2 Diabetes (T2D), particularly patients with established atherosclerotic cardiovascular disease (ASCVD). Given this, they are now recommended therapy for patients with diabetes and established or high risk of ASCVD.
Given the known inequitable utilization of other therapies, along with the known higher burden of diabetes and cardiovascular disease among Black patients, the aim of this study was to evaluate the uptake of GLP-1 RA as well as for inequities in utilization.